Cirrus таблетки инструкция

Наши контакты:

Telegram:

==============================

Cirrus Duo (Cirrus), tabletki o przedłużonym uwalnianiu, 6 szt.

Cirrus включает в себя два активных вещества: цетиризина dichlorowodorek и pseudoefedryny гидрохлорид. Остальные ингредиенты это: В состав слоя с пролонгированным высвобождением входят: hypromeloza,целлюлоза микрокристаллическая, кремний коллоидный безводный, магния стеарат. В состав оболочки Opadry Y white входят: hypromeloza, титана диоксид Е , макрогол Этот препарат следует использовать точно так, как это описано в листовке для пациента или по рекомендации врача или фармацевта. В случае сомнений следует обратить посылаю к врачу или фармацевту. Рекомендуемая доза препарата Cirrus у взрослых-одна таблетка два раза в сутки утром и вечером во время еды или между приемами пищи. Таблетки Cirrus нельзя сокрушить, раздавить, жевать или дробить. Препарат следует проглатывать целиком, запивая достаточным количеством жидкости. Если симптомы ухудшаются или не улучшаются после 5 дней, обратитесь к врачу. Срок применения препарата Cirrus не должен превышать периода возникновения симптомов и не должно быть больше, чем 2 до 3 недель. Врач может рекомендовать применение же цетиризин в продолжении лечения. Цетиризин dichlorowodorek является препаратом przeciwalergicznym, а pseudoefedryny гидрохлорид сужает сосуды в слизистой оболочке носа, в результате чего снижается гиперемия слизистой оболочки носа. Cirrus, таблетки с пролонгированным высвобождением показан для лечения симптомов сезонного и круглогодичного аллергического ринита, таких как: заложенности носа заложенность носа , чихание, водянистые выделения из носа насморк и зуд зуд носа и конъюнктивы. Препарат предназначен для применения в тех случаях, когда желательно как действие, противоаллергическое действие цетиризина dichlorowodorku, как и уменьшающие заложенность носа действие pseudoefedryny гидрохлорида. Как и любой препарат, этот препарат может вызывать побочные эффекты, хотя не у каждого они возникнут. Побочные эффекты, возникающие: часто могут возникать у 1 до 10 на пациентов :. Препарат содержит лактозу. Если было установлено ранее у пациента непереносимость некоторых сахаров, пациент должен проконсультироваться с врачом перед приемом препарата. Вам следует сообщить врачу или фармацевту обо всех лекарственных средствах, принимаемых пациентом в настоящее время или недавно, а также о лекарствах, которые пациент планирует использовать. Некоторые лекарства, если принимаются вместе с препаратом Cirrus, могут вызвать побочные эффекты. Если пациентка беременна или кормит грудью, предполагает, что может быть при беременности или когда планируете иметь ребенка, должна посоветоваться с врачом или фармацевтом перед использованием этого препарата. Препарата Cirrus не следует применять в период кормления грудью, так как cetyryzyna и псевдоэфедрин проникают в грудное молоко. Применение препарата Cirrus у детей в возрасте до 12 лет противопоказано, так как соединения активных веществ, присутствующих в препарата Cirrus не изучались в этой возрастной группе, а также благодаря содержанию одного из активных веществ, т. Перед применением следует обратиться к врачу. В проведенных исследованиях cetyryzyna в рекомендуемых дозах не оказывало существенного влияния на способность к вождению автотранспорта и фитнес форме. У некоторых людей, принимающих участие в исследованиях выступала сонливость. Cetyryzyna в дозах, превышающих рекомендуемые, может влиять на центральную нервную систему. Тем не менее, не зафиксировано и не ожидается негативного влияния pseudoefedryny. Поэтому рекомендуется, чтобы пациенты водить транспортные средства или обслуживающий машины сохранили осторожность, не применять в дозе, превышающей рекомендуемую, и учли возможность возникновения побочных эффектов. Пациенты не должны управлять автотранспортом, если они испытывают сонливость или головокружение. Описание Cirrus включает в себя два активных вещества: цетиризина dichlorowodorek и pseudoefedryny гидрохлорид. Состав 1 таблетка содержит : dichlorowodorek 5 мг цетиризина в форме с немедленным высвобождением и гидрохлорид pseudoefedryny мг в форме с пролонгированным высвобождением. Дозировка Этот препарат следует использовать точно так, как это описано в листовке для пациента или по рекомендации врача или фармацевта. Длительность лечения Если симптомы ухудшаются или не улучшаются после 5 дней, обратитесь к врачу. Действие Цетиризин dichlorowodorek является препаратом przeciwalergicznym, а pseudoefedryny гидрохлорид сужает сосуды в слизистой оболочке носа, в результате чего снижается гиперемия слизистой оболочки носа. Показания Cirrus, таблетки с пролонгированным высвобождением показан для лечения симптомов сезонного и круглогодичного аллергического ринита, таких как: заложенности носа заложенность носа , чихание, водянистые выделения из носа насморк и зуд зуд носа и конъюнктивы. Побочные эффекты Как и любой препарат, этот препарат может вызывать побочные эффекты, хотя не у каждого они возникнут. Побочные эффекты, возникающие: часто могут возникать у 1 до 10 на пациентов : - нервозность - бессонница - головокружение, головные боли - сонливость - ускорение работы сердца - сухость слизистой оболочки полости рта - тошнота - чувство слабости - беспокойство - стимулирование - реакции повышенной чувствительности - галлюцинации - судороги, тремор - нарушения ритма сердца - бледность кожных покровов - высокое кровяное давление - рвота - нарушение функции печени повышение активности трансаминаз, щелочной фосфатазы, гамма-glutamylotransferazy, повышение концентрации билирубина - сухость кожи, сыпь, повышенное потоотделение, крапивница - болезненное или затрудненное мочеиспускание Предупреждения и меры предосторожности Перед началом применения препарата Cirrus следует обсудить это с вашим врачом или фармацевтом. Применение других лекарственных средств Вам следует сообщить врачу или фармацевту обо всех лекарственных средствах, принимаемых пациентом в настоящее время или недавно, а также о лекарствах, которые пациент планирует использовать. Применение препарата с едой и напитками Препарат Cirrus можно применять во время еды или между приемами пищи. Беременность и кормление грудью Если пациентка беременна или кормит грудью, предполагает, что может быть при беременности или когда планируете иметь ребенка, должна посоветоваться с врачом или фармацевтом перед использованием этого препарата. Препарат не следует применять в период беременности. Применение препарата у детей и подростков Применение препарата Cirrus у детей в возрасте до 12 лет противопоказано, так как соединения активных веществ, присутствующих в препарата Cirrus не изучались в этой возрастной группе, а также благодаря содержанию одного из активных веществ, т. Управление автотранспортом и работа с механизмами В проведенных исследованиях cetyryzyna в рекомендуемых дозах не оказывало существенного влияния на способность к вождению автотранспорта и фитнес форме. Добро пожаловать в , для того, чтобы узнать расположении ближайшей аптеки, которая реализует ваш заказ. Доставка в аптеки по всей стране осуществляется бесплатно в течение h. Похожие товары. Xylodex 0.

Купить закладку гашиша Москва Алексеевский

Cirrus таблетки инструкция

Закладки экстази Новороссийск

Заказать кокаин с доставкой Силуэт

Cirrus таблетки инструкция

Купить закладку Шишек Салоники

Купить крис закладкой Балашиха

Cirrus таблетки инструкция

Марихуана шишки и бошки Москва Южное Бутово

Скорость (ск) a-PVP купить Москва Бирюлёво Восточное

Купить меф закладкой Ессентуки

Закладки скорости (ск) a-PVP Волжский

Cirrus таблетки инструкция

Купить героин закладкой Валь-ди-Фасса

подскажите , пожалуйста , информацию о лекарсве CIRRUS ? Выписали ребенку и я хочу знать, ЧТО.

Скорость (ск) a-PVP Тоскана

Купить закладку кокаина Пуэрто-Морелос

Attention: Information on this site is provided for informational purposes and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for treating a health problem or disease, or prescribing any medication. Tablets also contain as inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose. The molecular weight is Cetirizine hydrochloride is a white, crystalline powder and is water-soluble. The chemical structure is shown below:. Pseudoephedrine hydrochloride occurs as fine, white to off-white crystals or powder, having a faint characteristic odor. It is very soluble in water, freely soluble in alcohol, and sparingly soluble in chloroform. Cetirizine, a metabolite of hydroxyzine, is an antihistamine; its principal effects are mediated via selective inhibition of H 1 receptors. The antihistaminic activity of cetirizine has been clearly documented in a variety of animal and human models. In vivo and Ex vivo animal models have shown negligible anticholinergic and antiserotonergic activity. In clinical trials, however, dry mouth was more common with cetirizine than with placebo. In vitro receptor binding studies have shown no measurable affinity for other than H 1 receptors. Autoradiographic studies with radiolabeled cetirizine in the rat have shown negligible penetration into the brain. Ex vivo experiments in the mouse have shown that systemically administered cetirizine does not significantly occupy cerebral H 1 receptors. Pseudoephedrine hydrochloride is an orally active sympathomimetic amine and exerts a decongestant action on the nasal mucosa. Pseudoephedrine hydrochloride is recognized as an effective agent for the relief of nasal congestion due to allergic rhinitis. Pseudoephedrine produces peripheral effects similar to those of ephedrine and central effects similar to, but less intense than, amphetamines. It has the potential for excitatory side effects. The bioavailability of cetirizine hydrochloride and pseudoephedrine hydrochloride from ZYRTEC-D 12 HOUR Extended Release Tablets is not significantly different from that achieved with separate administration of a cetirizine 5 mg tablet and a pseudoephedrine mg extended release caplet. Co-administration of cetirizine and pseudoephedrine does not significantly affect the bioavailability of either component. Food had no significant effect on the extent of cetirizine absorption AUC , but Tmax was delayed by 1. Food had no significant effect on the pharmacokinetics of pseudoephedrine. No plasma protein binding data in humans are available. Most of the rapid increase in peak plasma radioactivity was associated with parent drug, suggesting low first pass metabolism. Cetirizine is metabolized to a limited extent by oxidative O-dealkylation to a metabolite with negligible antihistaminic activity. The enzyme or enzymes responsible for this metabolism have not been identified. One to seven percent of the pseudoephedrine dose appeared to be metabolized to norpseudoephedrine by N-demethylation after a single dose. It was reported that 0. Pharmacokinetic interaction trials with cetirizine in adults were conducted with pseudoephedrine, antipyrine, ketoconazole, erythromycin and azithromycin. No interactions were observed. The disposition of theophylline was not altered by concomitant cetirizine administration. The decrease in cetirizine clearance in these elderly volunteers may be related to decreased renal function. The effect of gender on cetirizine or pseudoephedrine pharmacokinetics has not been adequately studied. The effect of race on cetirizine or pseudoephedrine pharmacokinetics has not been adequately studied. The pharmacokinetics of cetirizine were similar in patients with mild impairment and normal volunteers. Therefore, pseudoephedrine may accumulate in patients with renal insufficiency. Trials in 69 adult normal volunteers aged 20—61 years showed that cetirizine at doses of 5 and 10 mg inhibited the skin wheal and flare caused by the intradermal injection of histamine. The effects of intradermal injection of various other mediators or histamine releasers were also inhibited by cetirizine. In mildly asthmatic subjects, cetirizine at 5 to 20 mg blocked bronchoconstriction due to nebulized histamine, with virtually total blockade after a 20 mg dose. In trials conducted for up to 12 hours following cutaneous antigen challenge, the late phase recruitment of eosinophils, neutrophils and basophils, components of the allergic inflammatory response, was inhibited by cetirizine at a dose of 20 mg. The clinical significance of these findings is not known. In four clinical trials in healthy adult males, no clinically significant mean increases in QTc were observed in cetirizine treated subjects. In the first study, a placebo-controlled crossover trial, cetirizine was given at doses up to 60 mg per day, 6 times the maximum clinical dose, for 1 week, and no significant mean QTc prolongation occurred. In the second study, a crossover trial, cetirizine 20 mg and erythromycin mg every 8 hours were given alone and in combination. There was no significant effect on QTc with the combination or with cetirizine alone. In the third trial, also a crossover study, cetirizine 20 mg and ketoconazole mg per day were given alone and in combination. Cetirizine caused a mean increase in QTc of 9. Ketoconazole also increased QTc by 8. The combination caused an increase of Thus, there was no significant drug interaction on QTc with the combination of cetirizine and ketoconazole. In the fourth study, a placebo-controlled parallel trial, cetirizine 20 mg was given alone or in combination with azithromycin mg as a single dose on the first day followed by mg once daily. There was no significant increase in QTc with cetirizine 20 mg alone or in combination with azithromycin. In a six-week, placebo-controlled study of patients aged 12—64 years with allergic rhinitis and mild to moderate asthma, cetirizine 10 mg once daily improved rhinitis symptoms and did not alter pulmonary function. This study supports the safety of administering cetirizine to allergic rhinitis patients with mild to moderate asthma. In the two trials, patients were aged 12 to 17 years. The primary efficacy measure in both trials was the mean change from baseline in the subject-rated Total Symptom Severity Complex TSSC score, which included the following symptoms: sneezing, runny nose, itchy nose, itchy eyes, watery eyes, postnasal drip, and nasal congestion. Nine multicenter, randomized, double-blind, clinical trials comparing cetirizine 5 to 20 mg to placebo in patients 12 years and older with seasonal or perennial allergic rhinitis were conducted in the United States. Five of these showed significant reductions in symptoms of allergic rhinitis, 3 in seasonal allergic rhinitis 1 to 4 weeks in duration and 2 in perennial allergic rhinitis for up to 8 weeks in duration. In general, the 10 mg dose was more effective than the 5 mg dose and the 20 mg dose gave no added effect. Some of these trials included pediatric patients aged 12 to 16 years. It is also contraindicated in patients with severe hypertension, or severe coronary artery disease, and in those who have shown hypersensitivity or idiosyncrasy to its components, to adrenergic agents, or to other drugs of similar chemical structures. Manifestations of patient idiosyncrasy to adrenergic agents include insomnia, dizziness, weakness, tremor, or arrhythmias. Sympathomimetic amines may produce central nervous system stimulation with convulsions or cardiovascular collapse with accompanying hypotension. The elderly are more likely to have adverse reactions to sympathomimetic amines. Cetirizine hydrochloride and pseudoephedrine hydrochloride do not influence the pharmacokinetics of each other when administered concomitantly. No clinically significant drug interactions have been found with cetirizine and theophylline at a low dose, azithromycin, ketoconazole, or erythromycin. There was a small decrease in the clearance of cetirizine caused by a mg dose of theophylline; it is possible that larger theophylline doses could have a greater effect. Concomitant use with antihypertensive drugs that interfere with sympathetic activity e. Increased ectopic pacemaker activity can occur when pseudoephedrine is used concomitantly with digitalis. There are no carcinogenicity trials of pseudoephedrine and cetirizine in combination. Cetirizine was not mutagenic in the Ames test or mouse lymphoma test and not clastogenic in the human lymphocyte assay or the in vivo rodent micronucleus test. Likewise, the combination of cetirizine and pseudoephedrine in a ratio was not mutagenic or clastogenic in these tests. However, the Ames and mouse lymphoma assays did not strictly adhere to test standards. These effects were not observed at 1. This effect was not observed at 1. For pseudoephedrine administered alone, 0. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, although the elderly are more likely to have adverse reactions to sympathomimetic amines. In general, dosing in an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Of the total number of subjects in clinical trials of cetirizine alone, were 65 years and over, while 39 were 75 years and over. No overall differences in safety were observed between these subjects and younger subjects, and other reported experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. With regard to efficacy, clinical trials of cetirizine for each approved indication did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently than younger patients. This dose of pseudoephedrine exceeds the recommended dose for pediatric patients under 12 years of age. Controlled and uncontrolled clinical trials of cetirizine conducted in the United States and Canada included more than patients aged 12 years and older, with more than receiving cetirizine at doses of 5 to 20 mg per day. The duration of treatment ranged from 1 week to 6 months, with a mean exposure of 30 days. Most adverse reactions reported during therapy with cetirizine were mild or moderate. In placebo-controlled trials, the incidence of discontinuations due to adverse reactions in patients receiving cetirizine 5 mg or 10 mg was not significantly different from placebo 2. The most common adverse reaction in patients aged 12 years and older that occurred more frequently on cetirizine than placebo was somnolence. Discontinuations due to somnolence for cetirizine were uncommon 1. Fatigue and dry mouth also appeared to be treatment-related adverse reactions. There were no differences by age, race, gender or by body weight with regard to the incidence of adverse reactions. Table 2 lists adverse experiences in patients aged 12 years and older that were reported for cetirizine 5 and 10 mg in controlled clinical trials in the United States and were more common with cetirizine than placebo. A causal relationship of these infrequent events with cetirizine administration has not been established. Autonomic Nervous System: anorexia, flushing, increased salivation, urinary retention. Cardiovascular: cardiac failure, hypertension, palpitation, tachycardia. Central and Peripheral Nervous Systems: abnormal coordination, ataxia, confusion, dysphonia, hyperesthesia, hyperkinesia, hypertonia, hypoesthesia, leg cramps, migraine, myelitis, paralysis, paresthesia, ptosis, syncope, tremor, twitching, vertigo, visual field defect. Gastrointestinal: abnormal hepatic function, aggravated tooth caries, constipation, dyspepsia, eructation, flatulence, gastritis, hemorrhoids, increased appetite, melena, rectal hemorrhage, stomatitis including ulcerative stomatitis, tongue discoloration, tongue edema. Genitourinary: cystitis, dysuria, hematuria, micturition frequency, polyuria, urinary incontinence, urinary tract infection. Musculoskeletal: arthralgia, arthritis, arthrosis, muscle weakness, myalgia. Psychiatric: abnormal thinking, agitation, amnesia, anxiety, decreased libido, depersonalization, depression, emotional lability, euphoria, impaired concentration, insomnia, nervousness, paroniria, sleep disorder. Respiratory System: bronchitis, dyspnea, hyperventilation, increased sputum, pneumonia, respiratory disorder, rhinitis, sinusitis, upper respiratory tract infection. Reproductive: dysmenorrhea, female breast pain, intermenstrual bleeding, leukorrhea, menorrhagia, vaginitis. Skin: acne, alopecia, angioedema, bullous eruption, dermatitis, dry skin, eczema, erythematous rash, furunculosis, hyperkeratosis, hypertrichosis, increased sweating, maculopapular rash, photosensitivity reaction, photosensitivity toxic reaction, pruritus, purpura, rash, seborrhea, skin disorder, skin nodule, urticaria. Vision: blindness, conjunctivitis, eye pain, glaucoma, loss of accommodation, ocular hemorrhage, xerophthalmia. Body as a Whole: accidental injury, asthenia, back pain, chest pain, enlarged abdomen, face edema, fever, generalized edema, hot flashes, increased weight, leg edema, malaise, nasal polyp, pain, pallor, periorbital edema, peripheral edema, rigors. Occasional instances of transient, reversible hepatic transaminase elevations have occurred during cetirizine therapy. Hepatitis with significant transaminase elevation and elevated bilirubin in association with the use of cetirizine has been reported. In foreign marketing experience or experience in the post market period, the following additional rare, but potentially severe adverse events have been reported: anaphylaxis, cholestasis, glomerulonephritis, hemolytic anemia, hepatitis, orofacial dyskinesia, severe hypotension, stillbirth, thrombocytopenia, aggressive reaction and convulsions. Pseudoephedrine hydrochloride may cause mild CNS stimulation in hypersensitive patients. Nervousness, excitability, restlessness, dizziness, weakness, or insomnia may occur. Headache, nausea, drowsiness, tachycardia, palpitation, pressor activity, and cardiac arrhythmias have been reported. Sympathomimetic drugs have also been associated with other untoward effects such as fear, anxiety, tenseness, tremor, hallucinations, seizures, pallor, respiratory difficulty, dysuria, and cardiovascular collapse. Information regarding acute overdosage is limited to experience with cetirizine alone and the marketing history of pseudoephedrine hydrochloride. Overdosage has been reported with cetirizine. In one adult patient who took mg of cetirizine, the patient was somnolent but did not display any other clinical signs or abnormal blood chemistry or hematology results. In an month-old pediatric patient who took an overdose of cetirizine approximately mg , restlessness and irritability were observed initially; this was followed by drowsiness. Should overdose occur, treatment should be symptomatic or supportive, taking into account any concomitantly ingested medications. There is no known specific antidote to cetirizine. Cetirizine is not effectively removed by dialysis, and dialysis will be ineffective unless a dialyzable agent has been concomitantly ingested. In rodents, the target of acute toxicity was the central nervous system, and the target of multiple-dose toxicity was the liver. In large doses, sympathomimetics may give rise to giddiness, headache, nausea, vomiting, sweating, thirst, tachycardia, precordial pain, palpitations, difficulty in micturition, muscular weakness and tenseness, anxiety, restlessness, and insomnia. Many patients can present a toxic psychosis with delusions and hallucinations. Some may develop cardiac arrhythmias, circulatory collapse, convulsions, coma and respiratory failure. Norwegian Institute of Public Health - \\\\\\\\\[Nov\\\\\\\\\]. All rights reserved. N14 R x Meda Pharma 6. Pharmacokinetics Absorption The bioavailability of cetirizine hydrochloride and pseudoephedrine hydrochloride from ZYRTEC-D 12 HOUR Extended Release Tablets is not significantly different from that achieved with separate administration of a cetirizine 5 mg tablet and a pseudoephedrine mg extended release caplet. Drug Interactions Pharmacokinetic interaction trials with cetirizine in adults were conducted with pseudoephedrine, antipyrine, ketoconazole, erythromycin and azithromycin. The pharmacokinetics of pseudoephedrine has not been adequately studied in geriatric subjects. Gender The effect of gender on cetirizine or pseudoephedrine pharmacokinetics has not been adequately studied. Race The effect of race on cetirizine or pseudoephedrine pharmacokinetics has not been adequately studied. The effect of hepatic impairment on pseudoephedrine pharmacokinetics is unknown. Pharmacodynamics Trials in 69 adult normal volunteers aged 20—61 years showed that cetirizine at doses of 5 and 10 mg inhibited the skin wheal and flare caused by the intradermal injection of histamine. Zyrtec Tablets Nine multicenter, randomized, double-blind, clinical trials comparing cetirizine 5 to 20 mg to placebo in patients 12 years and older with seasonal or perennial allergic rhinitis were conducted in the United States. Drug Interactions Cetirizine hydrochloride and pseudoephedrine hydrochloride do not influence the pharmacokinetics of each other when administered concomitantly. Carcinogenesis, Mutagenesis and Impairment of Fertility There are no carcinogenicity trials of pseudoephedrine and cetirizine in combination. Cetirizine Of the total number of subjects in clinical trials of cetirizine alone, were 65 years and over, while 39 were 75 years and over. TABLE 1. TABLE 2. Hearing and Vestibular: deafness, earache, ototoxicity, tinnitus. Reticuloendothelial: lymphadenopathy. Special Senses: parosmia, taste loss, taste perversion. Pseudoephedrine Hydrochloride Pseudoephedrine hydrochloride may cause mild CNS stimulation in hypersensitive patients. Valga selveri apteek. N14 R x Meda Pharma. A-aptieka Riga.

Cirrus таблетки инструкция

Купить амфетамин Выборг

Купить кокс Москва Таганский

Cirrus таблетки инструкция

Купить закладку метадона Португалия